Drug Profile
Research programme: small molecule therapeutics - Amgen/Infinity Pharmaceuticals
Latest Information Update: 11 Sep 2008
Price :
$50
*
At a glance
- Originator Amgen; Infinity Pharmaceuticals
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 20 Jul 2006 Amgen has extended its collaboration agreement with Infinity
- 13 Jan 2004 Preclinical trials in Undefined in USA (unspecified route)